Abstract
We retrospectively investigated the outcome of 30 newly diagnosed patients with mantle cell lymphoma treated with high-dose therapy and autologous stem cell transplantation in first response. With a median follow-up of 55 months, the 5-year overall-survival is 62%, the 5-year progression-free-survival is 40% and no secondary malignancy has occurred.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Lymphoma, Mantle-Cell / mortality
-
Lymphoma, Mantle-Cell / surgery*
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Retrospective Studies
-
Stem Cell Transplantation / methods*
-
Survival Analysis
-
Transplantation, Autologous
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone